scispace - formally typeset
D

Douglass C. Tormey

Researcher at University of Wisconsin-Madison

Publications -  163
Citations -  33755

Douglass C. Tormey is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 58, co-authored 163 publications receiving 31773 citations. Previous affiliations of Douglass C. Tormey include National Institutes of Health & Eastern Cooperative Oncology Group.

Papers
More filters
Journal ArticleDOI

Toxicity and response criteria of the Eastern Cooperative Oncology Group

TL;DR: The Eastern Cooperative Oncology Group criteria for toxicity and response are presented to facilitate future reference and to encourage further standardization among those conducting clinical trials.
Journal ArticleDOI

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

O. Abe, +412 more
- 14 May 2005 - 
TL;DR: The 10-year and 15-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival are reported and it is found that the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis.
Journal Article

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

C. Focan, +226 more
- 18 Sep 1998 - 
TL;DR: The age-specific benefits of polychemotherapy appeared to be largely irrespective of menopausal status at presentation, oestrogen receptor status of the primary tumour, and of whether adjuvant tamoxifen had been given.
Journal ArticleDOI

Prognostic effect of weight loss prior tochemotherapy in cancer patients

TL;DR: The prognostic effect of weight loss prior to chemotherapy was analyzed using data from 3,047 patients enrolled in 12 chemotherapy protocols of the Eastern Cooperative Oncology Group and increased with increasing number of anatomic sites involved with metastases, but within categories of Anatomic involvement, weight loss was associated with decreased median survival.
Journal ArticleDOI

Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma

TL;DR: Adjuvant therapy with levamisole and fluorouracil should be standard treatment for Stage C colon carcinoma, and this approach should be readily adaptable to conventional medical practice.